MA40354A - Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer - Google Patents

Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer

Info

Publication number
MA40354A
MA40354A MA040354A MA40354A MA40354A MA 40354 A MA40354 A MA 40354A MA 040354 A MA040354 A MA 040354A MA 40354 A MA40354 A MA 40354A MA 40354 A MA40354 A MA 40354A
Authority
MA
Morocco
Prior art keywords
aflibercept
predicting
suffering
cancer
treatment
Prior art date
Application number
MA040354A
Other languages
English (en)
Inventor
-Blondel Marielle Chiron
Diether Lambrechts
Emmanuelle Magherini
Vincent Thuillier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA40354A publication Critical patent/MA40354A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA040354A 2014-07-18 2015-07-16 Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer MA40354A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14306172 2014-07-18

Publications (1)

Publication Number Publication Date
MA40354A true MA40354A (fr) 2017-05-24

Family

ID=51220534

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040354A MA40354A (fr) 2014-07-18 2015-07-16 Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer

Country Status (26)

Country Link
US (2) US10501523B2 (fr)
EP (1) EP3170005B1 (fr)
JP (1) JP6685276B2 (fr)
KR (1) KR102486321B1 (fr)
CN (1) CN107076750B (fr)
AU (1) AU2015289124B2 (fr)
CA (1) CA2955302A1 (fr)
CY (1) CY1122233T1 (fr)
DK (1) DK3170005T3 (fr)
EA (1) EA035674B1 (fr)
ES (1) ES2732925T3 (fr)
HR (1) HRP20191145T1 (fr)
HU (1) HUE043951T2 (fr)
IL (1) IL250110B (fr)
LT (1) LT3170005T (fr)
MA (1) MA40354A (fr)
MX (1) MX2017000840A (fr)
PL (1) PL3170005T3 (fr)
PT (1) PT3170005T (fr)
RS (1) RS58957B1 (fr)
SG (1) SG11201700284UA (fr)
SI (1) SI3170005T1 (fr)
TR (1) TR201909951T4 (fr)
TW (1) TWI705247B (fr)
WO (1) WO2016008975A1 (fr)
ZA (1) ZA201700371B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TR201909951T4 (tr) 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
TWI746505B (zh) * 2016-01-25 2021-11-21 法商賽諾菲公司 通過測量血漿生物標記的水平預測疑似患有癌症的患者使用阿柏西普的治療的結果的方法
CN107602702A (zh) * 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
KR20220085906A (ko) * 2020-12-15 2022-06-23 삼천당제약주식회사 안과용 제형을 포함하는 시린지
WO2023153535A1 (fr) * 2022-02-09 2023-08-17 삼천당제약주식회사 Seringue contenant une formulation ophtalmique

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1993022336A1 (fr) 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Solubilisation et stabilisation ameliorees du complexe du facteur viii
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DK0694042T3 (da) 1993-03-25 2005-02-14 Merck & Co Inc Inhibitor af vaskulær endothelcellevækstfaktor
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
IL117684A (en) 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0928203B1 (fr) 1996-09-24 2006-10-25 Merck & Co., Inc. Composes servant a inhiber l'angiogenese par la therapie genique
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19724793A1 (de) 1997-06-06 1998-12-10 Schering Ag D-mutierte Peptide mit VEGF-Rezeptor blockierenden Eigenschaften
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2000034337A1 (fr) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Anticorps monoclonaux humanises luttant contre un facteur de croissance de cellules endotheliales vasculaires
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
BR0010017A (pt) 1999-04-28 2002-06-11 Univ Texas Composições e processos para o tratamento de câncer por inibição seletiva de vegf
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
NZ515913A (en) 1999-06-08 2004-01-30 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
DE19938724A1 (de) 1999-08-16 2001-02-22 Tetra Laval Holdings & Finance Vorrichtung zur Herstellung von Kunststoffbehältern mittels Streckblasformen
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
AR028424A1 (es) 2000-05-10 2003-05-07 Bayer Corp Metodo para regular la angiogenesis utilizando proteina ryk
WO2002030463A2 (fr) 2000-10-12 2002-04-18 Genentech, Inc. Formulations de proteine concentrees a viscosite reduite
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040023864A1 (en) 2001-05-09 2004-02-05 Steve Roczniak Method of regulating angiogenesis using ryk protein
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
KR20040091083A (ko) 2002-03-01 2004-10-27 파마시아 이탈리아 에스.피.에이. 이리노테칸 히드로클로라이드의 결정성 다형체
JP2004006671A (ja) 2002-03-22 2004-01-08 Sanyo Electric Co Ltd 電荷結合素子およびその製造方法
EP1608685B1 (fr) 2003-03-28 2007-02-21 Regeneron Pharmaceuticals, Inc. Antagonistes du facteur de croissance endotheliale pour le traitement du diabete
EP1610820B2 (fr) 2003-04-04 2013-08-21 Genentech, Inc. Preparations d'anticorps et de proteines a forte concentration
EP1626989A2 (fr) 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Methode de traitement du rejet de greffon corneen utilisant des antagonistes du facteur de croissance de l'endothelium vasculaire (vegf)
US7300654B2 (en) 2003-05-28 2007-11-27 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection in high risk keratoplasty patients
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CA2519875C (fr) 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Methode favorisant la regression de tumeurs au moyen d'inhibiteurs du vegf (facteur de croissance de l'endothelium vasculaire)
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050196340A1 (en) 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
WO2005016369A1 (fr) 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Utilisation d'un antagoniste des vegf en combinaison avec une radiotherapie
DK1660057T3 (da) 2003-08-27 2012-08-20 Ophthotech Corp Kombinationsterapi til behandling af neovaskulære øjenlidelser
DE60326353D1 (de) 2003-11-06 2009-04-09 Nestle Waters Man & Technology Herstellungsverfahren von Behältern aus Polyesterharz
WO2005046602A2 (fr) 2003-11-10 2005-05-26 Greenville Hospital System Antagonistes des recepteurs du vegf
WO2005072772A1 (fr) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Compositions pharmaceutiques
EP1753442A2 (fr) 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Methode d'administration et d'utilisation d'inhibiteurs de vegf pour le traitement d'un cancer humain
AU2005265071A1 (en) 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
CN1997386B (zh) 2004-07-30 2012-05-30 瑞泽恩制药公司 通过阻断vegf介导的活性来治疗i型糖尿病的方法
NZ596663A (en) 2004-10-21 2013-07-26 Genentech Inc Use of vegf antagonists in intraocular neovascular disease treatment
FR2878749B1 (fr) 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
WO2006088650A2 (fr) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Methode de traitement de lesion oculaire par l'administration locale d'un inhibiteur de vegf
US7354581B2 (en) 2005-02-11 2008-04-08 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
JP5737826B2 (ja) 2005-03-11 2015-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆの阻害による貧血の処置
US20060217311A1 (en) 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
US7531172B2 (en) 2005-08-12 2009-05-12 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a VEGF antagonist
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
CA2654510C (fr) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Formulations antagonistes du vegf appropriees a une administration intravitreenne
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008118846A1 (fr) 2007-03-23 2008-10-02 Precision Therapeutics, Inc. Procédés pour évaluer le potentiel angiogénique en culture
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
ES2578905T5 (es) 2007-10-04 2020-03-18 Onyx Therapeutics Inc Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos
EP2453234B1 (fr) * 2007-10-29 2014-01-15 Eisai R&D Management Co., Ltd. Procédés pour le pronostic de la capacité d'un composé à base d'un analogue de la zéaralénone à traiter le cancer
RS51987B (en) 2007-11-30 2012-02-29 Genentech Inc. VEGF POLYMORPHISMS AND ANTI-ANGIOGENESIC THERAPY
EP2143542A1 (fr) 2008-07-07 2010-01-13 Nestec S.A. Procédé et dispositif de conditionnement d'un liquide alimentaire
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
US20100047314A1 (en) 2008-08-22 2010-02-25 Osteogenex Inc. Folinic acid derivatives for promoting bone growth
WO2010042903A1 (fr) 2008-10-09 2010-04-15 Alfagene Bioscience, Inc Utilisation et identification de biomarqueurs pour les maladies gastro-intestinales
CA2740242A1 (fr) 2008-11-05 2010-05-14 Genentech, Inc. Polymorphismes genetiques dans la degenerescence maculaire liee a l'age
CA2754646A1 (fr) 2009-03-31 2010-10-07 Roche Glycart Ag Traitement du cancer par un anticorps anti-igg1 egfr humanise et par de l'irinotecane
WO2010124264A2 (fr) 2009-04-24 2010-10-28 University Of Southern California Variants génétiques dans la voie angiogénique en association avec un résultat clinique
MX2012000620A (es) 2009-07-13 2012-01-27 Genentech Inc Metodos diagnostico y composiciones para tratamiento de cancer.
JP5732458B2 (ja) 2009-07-31 2015-06-10 アムコー リミテッド 高温充填容器
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
KR20120104196A (ko) * 2009-10-02 2012-09-20 사일린 파마슈티칼스, 인크 Ｃｋ2 저해제에 대한 단백질 키나아제 ｃｋ2-매개의 질환의 감수성 및 반응을 예측하기 위한 바이오마커
KR20120116445A (ko) * 2009-12-25 2012-10-22 다이호야쿠힌고교 가부시키가이샤 간 세포암 환자에 대한 화학 요법의 치료 효과 예측 방법
CN105755112B (zh) * 2010-07-14 2019-06-07 视觉科技生物私人有限公司 结肠直肠癌的诊断
AU2012228544B2 (en) 2011-02-23 2015-06-11 Sanofi Single nucleotide polymorphisms in the promoter of VEGFA gene and their use as predictive markers for anti-VEGF treatments
TWI588156B (zh) * 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9945862B2 (en) * 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US20150037354A1 (en) * 2012-03-15 2015-02-05 The Resesrch Foundation for The State University of New York Combination therapies including inhibitors of the extracellular domain of e-cadherin
JP6019790B2 (ja) 2012-06-19 2016-11-02 富士電機株式会社 接合方法及び接合部材
WO2014020160A1 (fr) 2012-08-02 2014-02-06 Sanofi Article de manufacture comprenant de l'aflibercept ou du ziv-aflibercept
TR201909951T4 (tr) 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
TWI746505B (zh) 2016-01-25 2021-11-21 法商賽諾菲公司 通過測量血漿生物標記的水平預測疑似患有癌症的患者使用阿柏西普的治療的結果的方法

Also Published As

Publication number Publication date
EA201790211A1 (ru) 2017-05-31
CA2955302A1 (fr) 2016-01-21
AU2015289124B2 (en) 2021-03-11
LT3170005T (lt) 2019-07-10
IL250110B (en) 2020-04-30
KR102486321B1 (ko) 2023-01-09
EP3170005A1 (fr) 2017-05-24
MX2017000840A (es) 2017-05-04
PL3170005T3 (pl) 2019-10-31
PT3170005T (pt) 2019-07-16
TWI705247B (zh) 2020-09-21
US20170121387A1 (en) 2017-05-04
US11208461B2 (en) 2021-12-28
TR201909951T4 (tr) 2019-07-22
JP2017524127A (ja) 2017-08-24
HRP20191145T1 (hr) 2019-10-04
TW201619608A (zh) 2016-06-01
RS58957B1 (sr) 2019-08-30
HUE043951T2 (hu) 2019-09-30
CN107076750B (zh) 2020-06-23
DK3170005T3 (da) 2019-07-08
US20200157181A1 (en) 2020-05-21
EA035674B1 (ru) 2020-07-24
IL250110A0 (en) 2017-03-30
SG11201700284UA (en) 2017-02-27
CY1122233T1 (el) 2020-11-25
ZA201700371B (en) 2019-12-18
US10501523B2 (en) 2019-12-10
EP3170005B1 (fr) 2019-04-10
ES2732925T3 (es) 2019-11-26
AU2015289124A1 (en) 2017-02-09
WO2016008975A1 (fr) 2016-01-21
SI3170005T1 (sl) 2019-08-30
CN107076750A (zh) 2017-08-18
JP6685276B2 (ja) 2020-04-22
KR20170030631A (ko) 2017-03-17

Similar Documents

Publication Publication Date Title
MA40354A (fr) Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
IL283561B (en) Methods for treating eye diseases
HK1244293A1 (zh) 用cd3xcd20雙特異性抗體治療腫瘤的方法
HK1252272A1 (zh) 使用抗ox40抗體治療癌症的方法
EP3524689C0 (fr) Méthode de prédiction du pronostic chez une patiente atteinte du cancer du sein
IL276516A (en) Methods for diagnosing and treating inflammatory bowel disease
PL3169353T3 (pl) SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
PL3230731T3 (pl) Układ analityczny do analizy wody i ścieków
SG11201702103XA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
ZA201608820B (en) Method for treating drug resistant cancer
MA46970A (fr) Procédés de traitement de la maladie polykystique des reins
FR3016366B1 (fr) Bitume solide et son procede d'obtention
ZA201804318B (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
PL3292226T3 (pl) Sposób obróbki szlamu zawierającego żelazo
IL250080B (en) Treatment methods for patients with familial heterozygous hypercholesterolemia
FR3028617B1 (fr) Procede de depistage de l'amiante radioactive
MA41136A (fr) Composés pour le traitement d'un cancer
MA41824A (fr) Crépine et procédé de pompage associé
FI20146112A (fi) Menetelmä fosforin vähentämiseksi prosessista peräisin olevasta jätevedestä
TH1501004402A (th) แอ่งดักส่วนทางออกสำหรับกระชังปลา
FI20145573A (fi) Menetelmä suuren lujuuden omaavan dupleksisen ruostumattoman teräksen valmistamiseksi
TH1501003968A (th) วิธีการสำหรับการติดตั้งท่อทางเข้าและวิธีการสำหรับการรองรับท่อทางเข้า